Oppenheimer & Co. Inc. bought a new stake in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,478 shares of the company’s stock, valued at approximately $752,000.
Other institutional investors and hedge funds have also modified their holdings of the company. Sunbelt Securities Inc. grew its position in iShares U.S. Pharmaceuticals ETF by 14.3% during the 1st quarter. Sunbelt Securities Inc. now owns 960 shares of the company’s stock worth $83,000 after acquiring an additional 120 shares during the last quarter. Root Financial Partners LLC boosted its stake in iShares U.S. Pharmaceuticals ETF by 36.5% in the first quarter. Root Financial Partners LLC now owns 696 shares of the company’s stock worth $60,000 after purchasing an additional 186 shares in the last quarter. NewEdge Advisors LLC boosted its stake in iShares U.S. Pharmaceuticals ETF by 45.1% in the first quarter. NewEdge Advisors LLC now owns 1,397 shares of the company’s stock worth $121,000 after purchasing an additional 434 shares in the last quarter. Kestra Advisory Services LLC boosted its stake in iShares U.S. Pharmaceuticals ETF by 10.0% in the first quarter. Kestra Advisory Services LLC now owns 6,303 shares of the company’s stock worth $546,000 after purchasing an additional 571 shares in the last quarter. Finally, Trust Co. of Vermont bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the second quarter worth $60,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE stock opened at $106.72 on Wednesday. iShares U.S. Pharmaceuticals ETF has a 52 week low of $75.03 and a 52 week high of $109.43. The stock has a market capitalization of $1.61 billion, a PE ratio of 17.75 and a beta of 0.47. The stock’s fifty day moving average is $102.42 and its 200-day moving average is $94.95.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Featured Articles
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
